Alnylam Pharmaceuticals’ (NASDAQ:ALNY) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report issued on Monday, July 10th. The brokerage currently has a $131.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $110.00.

ALNY has been the topic of a number of other research reports. Credit Suisse Group restated a hold rating and set a $50.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 9th. ValuEngine raised Alnylam Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, June 13th. FBR & Co reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, March 20th. J P Morgan Chase & Co reaffirmed a hold rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 26th. Finally, Cowen and Company reaffirmed an outperform rating and set a $100.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, May 17th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $79.79.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 1.80% during trading on Monday, hitting $81.44. The stock had a trading volume of 732,039 shares. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $86.92. The stock’s market capitalization is $7.02 billion. The stock has a 50 day moving average price of $81.11 and a 200-day moving average price of $60.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. The firm had revenue of $19 million for the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The company’s revenue was up 160.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.21) EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($5.19) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/08/08/alnylam-pharmaceuticals-nasdaqalny-buy-rating-reaffirmed-at-chardan-capital-updated-updated-updated.html.

In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the completion of the sale, the executive vice president now directly owns 21,297 shares of the company’s stock, valued at approximately $1,597,275. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael Mason sold 9,375 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total value of $656,250.00. Following the sale, the vice president now directly owns 5,625 shares of the company’s stock, valued at $393,750. The disclosure for this sale can be found here. Insiders sold a total of 64,125 shares of company stock valued at $4,325,000 over the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the company. Bank of Montreal Can raised its stake in shares of Alnylam Pharmaceuticals by 283.6% in the first quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 7,044 shares in the last quarter. Peregrine Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 7.5% in the first quarter. Peregrine Capital Management LLC now owns 221,909 shares of the biopharmaceutical company’s stock worth $11,723,000 after buying an additional 15,477 shares in the last quarter. Macquarie Group Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 1,614 shares in the last quarter. Opus Point Partners Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 97.0% in the fourth quarter. Opus Point Partners Management LLC now owns 88,784 shares of the biopharmaceutical company’s stock worth $3,324,000 after buying an additional 43,720 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock worth $2,755,000 after buying an additional 7,048 shares in the last quarter. 88.96% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply